Fundraising FoxAvalon BioVentures — Full Portfolio
25 tracked investments · listed companies and verified rows first
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsCatalys PacificMPM BioImpact
Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications.
BiotechHealthtechLa Jolla, US
Miguel Garcia-Guzman(Co-Founder, CEO & Director)inCarolyn Bertozzi(Scientific Co-Founder)Jessica Stark(Scientific Co-Founder)inJames Lee(VP, Business Development)in
BoardStefan Heller(Director)Sanford Madigan(Director)in
Co-investorsCorrelation VenturesAlexandria
AristaMD is a technology-enabled clinical services provider that connects primary care physicians with board-certified specialists through eConsults to improve access to specialty care and reduce costs.
Digital HealthEnterprise SoftwareHealthtechSaaSSan Diego, US
Keith Pinter(Chief Executive Officer)inJulia Jezmir(President and Chief Medical Officer)inBrooke LeVasseur(Executive Officer, Director)inDouglas Downs(Executive Officer, Director)Rebecca Cofinas(Executive Officer, Director)
BoardJohn Kuelper(Director)in
Board seatJay B. Lichter· per SEC Form D · $1.4M raise · filed Mar 2016
Co-investorsAscension Ventures.406 VenturesCobalt VenturesCU Healthcare Innovation FundHomebrewMemorialCare Innovation Fund+2 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatJay B. Lichter· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Board seatKevin J. Kinsella· per SEC Form D
Co-investorsBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPfizer VenturesPolaris PartnersVersant Ventures
Co-investorsLifeX VenturesSanderling Ventures
AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers.
BiotechHealthtechLa Jolla, US
Ahmet Tutuncu(CEO and Co-founder)inAhmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)
BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)
Co-investorsAlexandriaCorrelation Ventures
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.
BiotechHealthtechSan Francisco, US
Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)inRory Riggs(Founder)
BoardRory B. Riggs(Director)
Co-investorsForesite CapitalRidgeback CapitalScientia VenturesMaverick Ventures
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.
BiotechHealthtechMedical DevicesSan Diego, US
Marc Nasoff(Chief Scientific Officer)
BoardJay B. Lichter(Ph.D.)in
Co-investorsVivo CapitalLilly Asia VenturesOUP (Osage University Partners)
Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)inTighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)inStefan Heller(Director)
Co-investorsOrbiMedSamsara BioCapital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cellular ApproachesCullinan MicaSynthorxAratana TherapeuticsArialys Therapeutics, Inc.CalportaCalporta TherapeuticsJanuxKorsa TherapeuticsNerio TherapeuticsPDI TherapeuticsProtalys TherapeuticsRQx PharmaRQx PharmaceuticalsSitari Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.